Jiangsu Hengrui Pharmaceuticals and its partner Elevar Therapeutics will have to wait even longer before their PD-1 inhibitor ...

Merck & Co. is handing over $200 million to China’s Hengrui Pharma for a phase 2-stage lipoprotein(a) (Lp(a)) inhibitor.

US regulators have once again declined to approve Hengrui Pharmaceuticals' (SHA: 600276) PD-1 inhibitor camrelizumab, further delaying the drug's entry into the American market.

Innovent and HUTCHMED received conditional approval for the combo in endometrial cancer from China’s NMPA last year.

Early results show that the combination of VXM01 plus avelumab demonstrated tolerable safety in recurrent glioblastoma.

test for pathway- and/or specific drug metabolism-related SNPs Dose/schedule alterations; crossover to a VEGFR–TKI with narrower specificity; sequential treatment with immunotherapy (if slowly ...

inhibitor Talzenna, the vascular endothelial growth factor receptor (VEGFR) inhibitor Inlyta (axitinib), the oral anti-coagulant Eliquis (apixaban), the transthyretin amyloid stabilizing drug ...

Oral presentation to highlight preclinical data further supporting combination of KO-2806 with TKIs in ccRCC – – Company expects to present data from the Phase 1 FIT-001 trial evaluating KO-2806 and ...

Treatment with VXM01, an investigational vaccine, plus Bavencio demonstrated both safety and tolerability in patients with ...